Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Tanner

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Transplantation and Cellular Therapy|September 6, 2023
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple MyelomaOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Cancer|December 21, 2023
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantationOren Pasvolsky, Sarah Pasyar, Roland L Bassett, et al.
British Journal of Haematology|March 6, 2024
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantationKamal Alzahrani, Oren Pasvolsky, Zhongya Wang, et al.
American Journal of Hematology|July 18, 2023
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experienceOren Pasvolsky, Denái R Milton, Adeel Masood, et al.
British Journal of Haematology|June 28, 2023
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplantOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Frontiers in Immunology|October 7, 2022
Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopeniaBijender Kumar, Vahid Afshar-Kharghan, Mayela Mendt, et al.
Blood Cancer Journal|May 17, 2024
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantationOren Pasvolsky, Zhongya Wang, Denái R Milton, et al.
Transplantation and Cellular Therapy|January 16, 2023
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center ExperienceOren Pasvolsky, Mahmoud R Gaballa, Denái R Milton, et al.
British Journal of Haematology|July 6, 2026
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myelomaCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Blood Cancer Journal|January 10, 2024
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experienceOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Transplantation and Cellular Therapy|September 6, 2023
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple MyelomaOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Cancer|December 21, 2023
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantationOren Pasvolsky, Sarah Pasyar, Roland L Bassett, et al.
British Journal of Haematology|March 6, 2024
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantationKamal Alzahrani, Oren Pasvolsky, Zhongya Wang, et al.
American Journal of Hematology|July 18, 2023
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experienceOren Pasvolsky, Denái R Milton, Adeel Masood, et al.
British Journal of Haematology|June 28, 2023
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplantOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Frontiers in Immunology|October 7, 2022
Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopeniaBijender Kumar, Vahid Afshar-Kharghan, Mayela Mendt, et al.
Blood Cancer Journal|May 17, 2024
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantationOren Pasvolsky, Zhongya Wang, Denái R Milton, et al.
Transplantation and Cellular Therapy|January 16, 2023
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center ExperienceOren Pasvolsky, Mahmoud R Gaballa, Denái R Milton, et al.
British Journal of Haematology|July 6, 2026
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myelomaCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Blood Cancer Journal|January 10, 2024
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experienceOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Pageof 5